Strategy Inc. vs Nuwellis Inc — how do they compare? Strategy Inc. trades at $154.16 (market cap $60.40B), while Nuwellis Inc trades at $0.68 (market cap $2.20M). The key difference: Strategy Inc. is far larger — about 27454.5× Nuwellis Inc's market cap, and Strategy Inc. is trading nearer its 52-week high, Nuwellis Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Strategy Inc. for 112 Days and Nuwellis Inc for 26 Days on average.
| MSTR | NUWE | |
|---|---|---|
Market Cap | $60.40B | $2.20M |
Volume | 23,421,830 | 121,544 |
Sector | Technology | Health |
52-Week High | $320.29 | $146.65 |
52-Week Low | $82.31 | $0.68 |
Typical Hold Time | 112 Days | 26 Days |
Enterprise Value | $79.16B | -$1.52M |
Signals from Pluang's Aura AI — not financial advice
MSTR stock trades at $153.37, down 6.79% today, reflecting volatility despite a bullish technical signal. The company reported a net loss of $3.85B in 2025 with a negative net income margin of -6,102.96%, though revenue grew slightly to $477.23M. Analyst consensus remains optimistic with a $252 price target, but earnings misses in recent quarters highlight operational challenges.
The outlook hinges on improving profitability and Bitcoin market stability, offering upside if earnings rebound. Key risks include persistent losses, high debt, and sensitivity to macroeconomic factors. Investors should weigh analyst optimism against fundamental weaknesses before considering a position.
NUWE trades at $0.6907, down 1.48% on the day, with a bearish technical signal from moving averages despite oversold RSI readings. The company reported revenue growth to $9M in 2026 but remains deeply unprofitable with a net income margin of -125.63%. Recent news highlights console sales growth and strategic expansions in pediatric and critical care markets.
The outlook is high-risk due to persistent losses and negative cash flow, though analyst sentiment is split with a 50% buy rating. Investment potential hinges on the company's ability to achieve profitability and scale its Aquadex platform, while risks include cash burn and competitive pressures in the medical device sector.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
MicroStrategy Inc is a provider of enterprise analytics and mobility software. It offers MicroStrategy Analytics platform that delivers reports and dashboards and enables users to conduct ad hoc analysis and share insights through mobile devices or the Web
Read more on MSTR →Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →